SGLT2 Inhibitors Sustaining Beta-Hydroxybutyrate Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for aortic aneurysms and dissections are ineffective in preventing disease progression, and existing methods to elevate beta-hydroxybutyrate (BHB) levels do not sustain therapeutic concentrations for extended periods.
Innovation Solution
The use of SGLT2 inhibitors alone or in combination with exogenous ketones, specifically beta-hydroxybutyrate (BHB), to achieve sustained therapeutic levels of BHB, which has anti-inflammatory and epigenetic effects beneficial for treating aortic aneurysms and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing methods to elevate BHB levels are used, then BHB concentration increases, but the elevation is not sustained for extended periods
Solution Approach 1:
The patent employs SGLT2 inhibitors as intermediary compounds that indirectly elevate and sustain BHB levels. Rather than administering BHB directly (which has short half-life), the SGLT2 inhibitor acts as a mediator that blocks BHB reabsorption in the kidneys, creating sustained endogenous production and circulation of BHB throughout the day.
Solution Approach 2:
The body's own metabolic system is harnessed to maintain therapeutic BHB levels. By inhibiting the SGLT2 transporter, the body naturally produces and circulates BHB without requiring external supplementation. The system uses the body's existing ketone production mechanisms, redirected to maintain elevated circulating levels through renal excretion blockade.
2Duration of action of moving object
If SGLT2 inhibitors are used to sustain BHB levels, then therapeutic duration is extended, but the mechanism involves renal excretion which may have side effects
Solution Approach 1:
The patent leverages the dose-dependent effects of SGLT2 inhibitors to achieve therapeutic BHB elevation while minimizing side effects. By optimizing the dosage to achieve moderate BHB levels (0.5-3.0 mM) rather than extreme ketosis, the treatment sustains therapeutic benefits while reducing the likelihood of renal and other adverse effects associated with higher doses.
3Reliability
If high doses of BHB are administered to achieve therapeutic levels, then efficacy increases, but compliance and safety decrease
Solution Approach 1:
The patent utilizes a once-daily oral medication (SGLT2 inhibitor) that provides sustained BHB elevation without requiring patients to administer multiple doses or undergo complex regimens. The single daily dose is convenient, affordable, and maintains therapeutic levels throughout the day, significantly improving compliance compared to requiring multiple BHB supplements or dietary restrictions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Sustained elevation of BHB levels using SGLT2 inhibitors and exogenous ketones effectively reduces inflammation, promotes vascular health, and provides therapeutic benefits for aortic aneurysms, heart failure, and other conditions.
Implementation Method 1
The use of SGLT2 inhibitors alone or in combination with exogenous ketones, specifically beta-hydroxybutyrate (BHB), to achieve sustained therapeutic levels of BHB
Implementation Method 2
The use of SGLT2 inhibitors alone or in combination with exogenous ketones, specifically beta-hydroxybutyrate (BHB), to achieve sustained therapeutic levels of BHB
Implementation Method 3
which has anti-inflammatory and epigenetic effects beneficial for treating aortic aneurysms and other conditions
Implementation Method 4
which has anti-inflammatory and epigenetic effects beneficial for treating aortic aneurysms and other conditions
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Compositions of compounds with SGLT2i activity in combination with compounds having BHB activity. These can be used in methods of treatment for a variety of human diseases such as cognitive deficits, Alzheimer's, kidney disease, heart failure and aortic aneurysms and dissection. The methods allow therapeutic levels of both SGLT2i and BHB activity to be achieved and maintained for as many hours per day as deemed optimal for the patient in need of therapy.